RxDoctor Payments DataLook up a doctor →

Yousuf Gaffar, MD

Hematology & Oncology · Denver, CONPI 1891798914

Payments from drug & device makers

$1,839,351in general payments, 2019–2025

Across 1,694 payments — averaging $1085.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$466K
  • Rigel Pharmaceuticals, Inc.$235K
  • E.r. Squibb & Sons, L.L.C.$224K
  • AstraZeneca$190K
  • Incyte Corporation$157K
  • Exelixis Inc.$142K
  • plus $425K from 54 others
$2,075in research payments, 2019–2025

Across 1 payment — averaging $2074.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC189$465,873
Rigel Pharmaceuticals, Inc.249$234,967
E.r. Squibb & Sons, L.L.C.145$223,522
AstraZeneca(2 entities)107$190,455
Incyte Corporation296$156,845
Exelixis Inc.116$142,155
Mirati Therapeutics, Inc.93$138,592
Novartis79$53,420
Dova Pharmaceuticals27$49,443
Seagen Inc.46$42,046
Takeda Pharmaceuticals U.S.A., Inc.35$40,770
Sobi, Inc21$28,574
CTI Biopharma Corp.3$12,857
Beigene USA, Inc.11$8,976
Pfizer17$8,665
AbbVie21$6,113
Genentech USA, Inc.20$5,603
Bristol Myers Squibb14$4,510
Daiichi Sankyo Inc.19$3,670
Tesaro, Inc.8$3,565
Bayer11$2,804
Karyopharm Therapeutics Inc.3$2,387
Puma Biotechnology, Inc.1$2,180
ADC Therapeutics America, Inc.5$2,036
EMD Serono, Inc.10$1,673
G1 Therapeutics, Inc.2$1,521
Beigene, Ltd.2$975
Sanofi10$899
Adaptive Biotechnologies Corporation2$764
Johnson & Johnson(2 entities)21$407
Sanofi-aventis U.S. LLC1$300
Merck11$259
Amgen13$239
Myriad Genetic Laboratories, Inc.4$232
Pharmacyclics LLC, An Abbvie Company4$195
Genmab U.S., Inc.2$190
GSK7$178
Lilly USA, LLC7$142
Gilead(2 entities)7$141
AVEO Pharmaceuticals, Inc.6$124
Eisai Inc.5$109
Boehringer Ingelheim4$82
Taiho Oncology, Inc.3$81
Astellas Pharma US Inc4$74
Tersera Therapeutics LLC3$71
Regeneron Healthcare Solutions, Inc.3$69
Array Biopharma Inc3$56
Spectrum Pharmaceuticals Inc.2$55
Sumitomo Pharma America, Inc.2$52
Myovant Sciences Inc.2$43
Secura Bio, Inc.1$40
Pharmacosmos Therapeutics Inc.2$36
Blue Earth Diagnostics1$35
Ipsen Biopharmaceuticals, Inc2$30
Pharmaessentia USA Corporation1$28
Dendreon Pharmaceuticals LLC1$26
Recordati_rare_diseases_inc.1$25
Morphosys, US Inc.1$25
Azurity Pharmaceuticals, Inc.1$22
Boston Scientific1$20

How this compares

$1,839,351 in reported general payments places this provider in the 85th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado →

Medicare billing

Part B allowed, 2024
$938,913
Medicare patients
296
Services billed
42,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Denver

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →